Drug Profile


Alternative Names: Bi20; FBTA05; Lymphomun

Latest Information Update: 27 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Chronic lymphocytic leukaemia in Germany (IV)
  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for B-cell lymphoma in Germany (IV)
  • 13 Jun 2010 Efficacy, adverse events and pharmacokinetics data from a compassionate use trial in Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia presented at the 15th Congress of the European Hematology Association (EHA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top